The INACTINE&#153;Pathogen Inactivation red blood cell product, currently entering a Phase II clinical trial, is designed to inactivate pathogens contained in red blood cells, the largest transfusion product market segment.
(Pathogen Inactivation red blood cell product; entering; a Phase II clinical trial; T:currently) (The INACTINE&#153;Pathogen Inactivation red blood cell product; is designed; to inactivate pathogens contained in red blood cells, the largest transfusion product market segment) (The INACTINE&#153;Pathogen Inactivation red blood cell product; to inactivate; pathogens contained in red blood cells) (pathogens; contained; in red blood cells)
Pathogen Inactivation red blood cell product The INACTINE&#153;Pathogen Inactivation red blood cell product The INACTINE&#153;Pathogen Inactivation red blood cell product pathogens
entering is designed to inactivate contained
a Phase II clinical trial T:currently
to inactivate pathogens contained in red blood cells, the largest transfusion product market segment
pathogens contained in red blood cells
in red blood cells